Ege \u00dcniversitesi (E\u00dc) T\u0131p Fak\u00fcltesi T\u0131bbi Biyoloji Ana Bilim Dal\u0131 \u00f6\u011fretim \u00fcyesi Do\u00e7. Dr. Nur Selvi G\u00fcnel\u2019in y\u00fcr\u00fct\u00fcc\u00fcl\u00fc\u011f\u00fcn\u00fc yapt\u0131\u011f\u0131 \u201cOver Kanseri Tedavisinde Dual Terapi: LPAR \u0130nhibisyonuna Y\u00f6nelik Polimer \u0130la\u00e7 Nanokonjugat\u0131n\u0131n Haz\u0131rlanmas\u0131, In vitro, In vivo ve Ex Vivo Ara\u015ft\u0131rmalar\u0131\u201d projesi, T\u00dcB\u0130TAK \u201c1001-Bilimsel ve Teknolojik Ara\u015ft\u0131rma Projelerini Destekleme Program\u0131\u201d kapsam\u0131nda desteklenmeye hak kazand\u0131. \u00a0Ege \u00dcniversitesi Rekt\u00f6r\u00fc Prof. Dr. Necdet Budak,\u00a0 proje y\u00fcr\u00fct\u00fcc\u00fcs\u00fc Do\u00e7. Dr. Nur Selvi G\u00fcnel\u2019i ve projenin ara\u015ft\u0131r\u0131c\u0131s\u0131 doktora \u00f6\u011frencisi Buket \u00d6zel’i makam\u0131nda a\u011f\u0131rlayarak, \u00e7al\u0131\u015fmalar\u0131nda ba\u015far\u0131lar diledi.<\/p>\n
Proje hakk\u0131nda bilgi veren Do\u00e7. Dr. G\u00fcnel, \u201cOver kanseri, t\u00fcm kad\u0131n kanserlerinin y\u00fczde 2,5’ini ve kad\u0131n kanseri ili\u015fkili \u00f6l\u00fcmlerin y\u00fczde 5’ini olu\u015fturan en \u00f6l\u00fcmc\u00fcl jinekolojik malignitedir. Over kanseri hastalar\u0131nda ge\u00e7 evrede tan\u0131 konmas\u0131 nedeniyle y\u00fcksek mortalite oranlar\u0131 g\u00f6r\u00fcl\u00fcr. Standart tedavi, bir platin bile\u015fi\u011fi ve bir taksan kombinasyonu sistemik kemoterapiden ve cerrahiden olu\u015fur. Hastalar\u0131n \u00e7o\u011fu bu t\u00fcr kombinasyon tedavilerine yan\u0131t olarak remisyon elde ederken, y\u00fczde 70’i platin diren\u00e7li bir t\u00fcm\u00f6rle n\u00fckseder ve bu noktada az say\u0131da tedavi se\u00e7ene\u011fi s\u00f6z konusudur. Over kanseri tedavisinde pek \u00e7ok strateji denense de hastal\u0131\u011f\u0131n n\u00fcks oran\u0131 y\u00fcksek, sa\u011f kal\u0131m oran\u0131 d\u00fc\u015f\u00fckt\u00fcr. Bu nedenle, over kanseri terapisinde hedefli terapiler dikkat \u00e7ekiyor\u201d dedi.<\/p>\n
\u201cBir\u00e7ok hasta i\u00e7in umut olacak\u201d<\/b><\/p>\n
Projenin ama\u00e7lar\u0131ndan bahseden Do\u00e7. Dr. G\u00fcnel, \u201cKanser \u00e7al\u0131\u015fmalar\u0131nda avantajlar\u0131 bilinen hedefli ila\u00e7 ta\u015f\u0131y\u0131c\u0131 sistem kullanarak, ikili terapi yakla\u015f\u0131m\u0131yla polimerik ila\u00e7 nanokonjugat\u0131 sentezlenecektir. Over kanserinde art\u0131\u015f\u0131 bilinen LPA resept\u00f6rlerinin inhibisyonu i\u00e7in bu resept\u00f6r\u00fcn se\u00e7ici inhibit\u00f6r\u00fc ve yine kanserde art\u0131\u015f\u0131, kanseri agresifle\u015ftiren tirozin kinazlar i\u00e7in bir inhibit\u00f6r olan ilac\u0131 i\u00e7eren polimerik ila\u00e7 nankonjugat\u0131 geli\u015ftirilecektir. Sentezlenecek polimerik nanokonjugat\u0131n yap\u0131s\u0131 itibariyle t\u00fcm\u00f6r mikro \u00e7evresinde par\u00e7alanmas\u0131yla a\u00e7\u0131\u011fa \u00e7\u0131kacak ila\u00e7 ve inhibit\u00f6r\u00fcn over kanseri h\u00fccrelerinde daha etkili ve hedefli olmas\u0131 beklenmektedir. \u00c7al\u0131\u015fma kapsam\u0131nda geli\u015ftirilecek nanokonjugat\u0131n over kanseri tedavi etkinli\u011fi ara\u015ft\u0131r\u0131lacakt\u0131r. Bir tirozin kinaz inhibit\u00f6r\u00fc ve bir LPA resept\u00f6r inhibit\u00f6r\u00fcn\u00fcn birlikte bir polimer ta\u015f\u0131y\u0131c\u0131 ile konjuge yap\u0131s\u0131 ve aralar\u0131ndaki ili\u015fki daha \u00f6nce \u00e7al\u0131\u015f\u0131lmam\u0131\u015ft\u0131r. Literat\u00fcrde buna benzer bir nanokonjugat yap\u0131s\u0131na rastlanmam\u0131\u015ft\u0131r. Tedavisi zorlay\u0131c\u0131 over kanseri i\u00e7in, ta\u015f\u0131y\u0131c\u0131 bir polimer \u00fczerinde bu iki inhibit\u00f6r\u00fc yap\u0131ya dahil etmenin over kanseri tedavisi i\u00e7in etkili olaca\u011f\u0131n\u0131 d\u00fc\u015f\u00fcnmekteyiz. Her y\u0131l d\u00fcnyada ve \u00fclkemizde over kanserinden dolay\u0131 ya\u015fam kalitesi d\u00fc\u015fm\u00fc\u015f bir\u00e7ok hasta i\u00e7in umut olma potansiyelindedir. Ayr\u0131ca, ulusal ve uluslararas\u0131 literat\u00fcre, \u00fclkemizin bilimsel geli\u015fimine katk\u0131 sa\u011flayaca\u011f\u0131 kanaatindeyiz\u201d diye konu\u015ftu.<\/p>\n","protected":false},"excerpt":{"rendered":"
Ege \u00dcniversitesi (E\u00dc) T\u0131p Fak\u00fcltesi T\u0131bbi Biyoloji Ana Bilim Dal\u0131 \u00f6\u011fretim \u00fcyesi Do\u00e7. Dr. Nur…<\/p>\n","protected":false},"author":2,"featured_media":4518,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[69,99,1,68],"tags":[],"class_list":["post-4517","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bilim","category-egitim","category-gncl","category-saglik"],"featured_image_urls":{"full":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/08\/12-Doc-Dr-Nur-Selvi-Gunel-scaled.jpg",2560,1843,false],"thumbnail":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/08\/12-Doc-Dr-Nur-Selvi-Gunel-150x150.jpg",150,150,true],"medium":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/08\/12-Doc-Dr-Nur-Selvi-Gunel-300x216.jpg",300,216,true],"medium_large":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/08\/12-Doc-Dr-Nur-Selvi-Gunel-768x553.jpg",640,461,true],"large":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/08\/12-Doc-Dr-Nur-Selvi-Gunel-1024x737.jpg",640,461,true],"1536x1536":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/08\/12-Doc-Dr-Nur-Selvi-Gunel-1536x1106.jpg",1536,1106,true],"2048x2048":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/08\/12-Doc-Dr-Nur-Selvi-Gunel-2048x1474.jpg",2048,1474,true],"newsphere-slider-full":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/08\/12-Doc-Dr-Nur-Selvi-Gunel-1280x720.jpg",1280,720,true],"newsphere-featured":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/08\/12-Doc-Dr-Nur-Selvi-Gunel-1024x737.jpg",1024,737,true],"newsphere-medium":["https:\/\/www.euegeajans.com\/wp-content\/uploads\/2021\/08\/12-Doc-Dr-Nur-Selvi-Gunel-720x380.jpg",720,380,true]},"author_info":{"display_name":"Editor","author_link":"https:\/\/www.euegeajans.com\/index.php\/author\/editor\/"},"category_info":"Bilim<\/a> E\u011fitim<\/a> G\u00fcncel<\/a> Sa\u011fl\u0131k<\/a>","tag_info":"Sa\u011fl\u0131k","comment_count":"0","_links":{"self":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts\/4517","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/comments?post=4517"}],"version-history":[{"count":2,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts\/4517\/revisions"}],"predecessor-version":[{"id":4530,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/posts\/4517\/revisions\/4530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/media\/4518"}],"wp:attachment":[{"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/media?parent=4517"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/categories?post=4517"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euegeajans.com\/index.php\/wp-json\/wp\/v2\/tags?post=4517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}